| Pharmicell to Bring Stem Cell Therapy to European Market |
|
Berlin, November 3, 2008 — Pharmicell received the official authorization for production of somatic cell therapeutics derived from adipose tissue. The license allows to produce and to market adipose tissue derived stem cells in Europe. With this permit, Pharmicell can provide its cell product (Twelve Cell Solution™) for a wide range of plastic-aesthetic therapies such as wrinkle and skin treatments, breast augmentation, and breast reconstruction after breast cancer surgery and radiation. Pharmicell’s cell production facility consists of high-end cleanroom laboratories following GMP (Good Manufacturing Practice) guidelines. Pharmicell is the first in Europe to provide GMP-certified fat cell products for clinical uses. Pharmicell has completed LOIs with Clinica Vita and Charité to introduce its products. The fat cell service will be available to German customers immediately. Pharmicell’s Twelve Cell Solution™ is produced from patient’s own fat tissue - derived cells, a composition consisting of stem cells, fat cells and other regenerating cell types, and the fat tissue is processed under GMP conditions to isolate the cells, which will then be reapplied to the patient. The fat tissue can be collected from normal liposuction procedure or from biopsies. The option for storage of the cells for later use will be available by 2009. Pharmicell Europe GmbH was founded in Berlin in 2006 to provide consumers with new adult stem cell therapies. Having completed preclinical trials for stroke and myocarditis with Charité and BCRT, Pharmicell intends to bring our cells into next phase of clinical trial. In 2009, Pharmicell will bring the new technology of using fat derived cells for plastic and aesthetic therapy to European customers. Pharmicell aims at opening a specialized stem cell treatment center and will collaborate closely with selected physicians and clinics to further develop the application of the product. As the European subsidiary of FCB Pharmicell Co. Ltd., based in South Korea, Pharmicell Europe’s R&D laboratories are located in the Center of Berlin and in the Europarc Dreilinden in Brandenburg which hosts Pharmicell’s GMP certified cell production area. Contact: Dr. Andreas Kurtz Tel. 030 3393 5994 Fax. 030 3393 5996 This e-mail address is being protected from spam bots, you need JavaScript enabled to view it www.pharmicell.eu
|